MAR 24, 2019 4:47 PM PDT

Generic Weight Loss Drug Safe & Effective for Long-Term Use

WRITTEN BY: Nouran Amin

In a study published in Obesity, an inexpensive weight-loss drug FDA-approved 60 years ago for a three month short-term use-- may now be regarded as safe and effective for longer-term treatment. The research was conducted by Wake Forest Baptist Health and the Patient Outcomes Research to Advance Learning (PORTAL) network.

"Although diet and exercise are critical components of any weight-loss program, up to half of patients don't have long-term success with lifestyle changes alone," said first author Kristina H. Lewis, M.D., assistant professor of epidemiology and prevention, at Wake Forest Baptist. "In those cases, medications or surgery can help. Generic phentermine is an effective and affordable option, but now that we view obesity as a chronic disease, it's important to have medications that can be used indefinitely. Most new weight-loss drugs are approved for long-term use, but unfortunately the newer drugs can be expensive if they are not covered by insurance."

The study concluded that individuals who stayed on phentermine longer will experience greater weight loss than those who stayed on the drug for three months or less. Additionally, longer-term analysis of the drug was not found to be associated with increases in blood pressure or an increased risk of heart attack, stroke or death. This is in similarity to other supplements such as Resurge.

"In general, the longer patients were on the medicine the more weight loss they had," Lewis said. "Not surprisingly, when patients stopped taking the medicine weight regain was common."

"For patients who respond to and tolerate it, phentermine may be a safe and affordable way to achieve greater and longer lasting weight loss, but we need clinical trials to provide more certainty," Lewis said. "At the moment, there is no change to the FDA labeling so doctors should use caution with the decision about prescribing it longer-term."

Source: Medical Xpress

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
SEP 21, 2020
Drug Discovery & Development
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
SEP 21, 2020
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
The World Health Organization has endorsed a protocol to put African herbal medicines through clinical trials as possibl ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 22, 2020
Cannabis Sciences
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
NOV 22, 2020
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescri ...
NOV 18, 2020
Technology
Using Machine Learning to Build Chemical Libraries
NOV 18, 2020
Using Machine Learning to Build Chemical Libraries
Using machine learning in drug discovery is no longer a novel procedure and has been well documented in recent literatur ...
NOV 15, 2020
Drug Discovery & Development
Drug Stimulates Female Fertility
NOV 15, 2020
Drug Stimulates Female Fertility
A recent drug, MVT-602, was found to stimulate fertility by acting on the natural 'kisspeptin' hormone system in ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
Loading Comments...